Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer

The purpose of this clinical trial is to assess the safety and efficacy of ubamatamab in combination with first-line chemotherapy in patients with ovarian cancer. The main questions it aims to answer are: * What is the safety profile of ubamatamab when administered with carboplatin-paclitaxel ± bevacizumab? * What is the objective response rate after three cycles of ubamatamab in combination with carboplatin-paclitaxel ± bevacizumab? Participants will: * Receive three cycles of ubamatamab in combination with carboplatin-paclitaxel ± bevacizumab, followed by maintenance therapy with ubamatamab ± bevacizumab for up to 15 months, depending on HRD status and disease response after the initial treatment cycles. * Attend regular clinic visits throughout the treatment period for checkups and tests

NCT Number	NCT07637851
Lead Sponsor	ARCAGY/ GINECO GROUP Collaborators: Regeneron Pharmaceuticals
Conditions	Ovarian Cancer
Enrollment	43 participants
Start Date	2026-08
Primary Completion	2028-09 (estimated)
Study Completion	2030-04 (estimated)
Updated on ClinicalTrials.gov	2026-07-10